ANAPTYSBIO, INC (ANAB) Stock Price, Financials & Summary

Price chart

Oct 1Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30

Key dataOct 30, 2026

Open$47.91

From 52W high−30.84%

Volume293611.00

Market cap$1.44B

P/E (TTM)7.2x

P/S (TTM)6.1x

Div yield—

Key dataOct 30, 2026

Open

$47.91

From 52W high

−30.84%

Volume

293611.00

Market cap

$1.44B

ValuationView details →

P/E (Fwd)

5.4x

EV/EBITDA

16.9x

P/E (TTM)

7.2x

RSI (14)

47.3

MomentumView details →

1D Return

−0.74%

YTD Return

+49.94%

SummaryUpdated Jun 1, 2026

AnaptysBio, Inc. (NASDAQ:ANAB) is a clinical-stage biotechnology company founded in 2005 and based in San Diego, California. The company was originally incorporated as Anaptys Biosciences, Inc. before changing its name to AnaptysBio in July 2006. AnaptysBio went public in January 2017 and focuses on developing innovative therapeutic antibody candidates for treating inflammatory diseases and immuno-oncology conditions. The company leverages its proprietary antibody discovery platform to create targeted treatments that modulate immune system responses.

Ask drillr about ANAPTYSBIO, INC →

ValuationView details →

P/E (Fwd)

5.4x

P/E (TTM)

7.2x

EV/EBITDA

16.9x

EV/Sales

6.5x

P/S (TTM)

6.1x

P/B (TTM)

136.4x

ProfitabilityView details →

Gross Margin

133.11%

Net Margin

82.37%

EBITDA Margin

38.68%

ROE (TTM)

1849.06%

ROA (TTM)

61.75%

Asset Turnover

0.73x

GrowthView details →

Revenue YoY

+92.92%

EPS YoY

+249.01%

FCF YoY

+114.11%

Revenue CAGR 3Y

+183.58%

EPS CAGR 3Y

+91.02%

EBITDA YoY

+254.08%

MomentumView details →

1D Return

−0.74%

YTD Return

+49.94%

1Y Return

+98.69%

RSI (14)

47.3

vs 50D SMA

−6.38%

vs 200D SMA

−3.86%

Capital & dividendView details →

Debt/Equity

25.47x

Current Ratio

5.61x

Quick Ratio

5.61x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$5.11

EPS Surprise

1198.92%

Beats (12Q)

6/12

Next Q EPS Est

$5.11

Avg Surprise (4Q)

237.63%

Rev Surprise

95.54%

Financials snapshotView financials →

Revenue (TTM)

237.61M

Net Income (TTM)

195.72M

Op. CF (TTM)

18.08M

Next earningsNov 3, 2026 →

Latest newsMore news →

AnaptysBio, Inc. reported a Q2 loss of $0.11 per share, beating the Zacks Consensus Estimate of a $0.46 loss and improving from a $1.34 loss per share a year earlier.42d ago

AnaptysBio, Inc. reported its financial results for the second quarter and transitional fiscal year ended June 30, 2026, and provided a business update.42d ago

Similar companies

Guangzhou Innogen Pharmaceutl Grp Co Ltd02591.HK Tyra Biosciences, Inc.TYRA KalVista Pharmaceuticals, Inc.KALV GH Research PLCGHRS PegBio Co., Ltd.02565.HK Rapport Therapeutics, Inc. Common StockRAPP Find similar companies →

Latest newsMore news →

AnaptysBio, Inc. reported a Q2 loss of $0.11 per share, beating the Zacks Consensus Estimate of a $0.46 loss and improving from a $1.34 loss per share a year earlier.42d ago AnaptysBio, Inc. reported its financial results for the second quarter and transitional fiscal year ended June 30, 2026, and provided a business update.42d ago